68Ga-Labeled Fibroblast Activation Protein Inhibitor (68Ga-FAPI) PET for Pancreatic Adenocarcinoma: Data from the 68Ga-FAPI PET Observational Trial

¹Department of Nuclear Medicine, University Hospital Essen, University of Duisburg-Essen, Essen, Germany;
²Department of Diagnostic and Interventional Radiology and Neuroradiology, University Hospital Essen, Essen, Germany;
³German Cancer Consortium (DKTK) (Partner Site University Hospital Essen) and German Cancer Research Center (DKFZ), Essen, Germany;
⁴Department of Medical Oncology, West German Cancer Center, University of Duisburg-Essen, Essen, Germany;
⁵Department of General and Visceral Surgery, St. Josef Hospital Bochum, Ruhr-University Bochum, Bochum, Germany;
⁶Department of Hematology and Oncology with Palliative Care, St. Josef-Hospital, Ruhr-University Bochum, Bochum, Germany;
⁷Department of General and Visceral Surgery, Alfried Krupp Hospital, Essen, Germany;
⁸Bridge Institute of Experimental Tumor Therapy, West German Cancer Center, University Hospital Essen, University of Duisburg-Essen, Essen, Germany; and
⁹Division of Solid Tumor Translational Oncology, German Cancer Consortium (DKTK) (Partner Site University Hospital Essen) and German Cancer Research Center (DKFZ), Heidelberg, Germany

For correspondence or reprints, contact Wolfgang P. Fendler (Wolfgang.fendler{at}uk-essen.de) or Jens T. Siveke (jens.siveke{at}uk-essen.de).

Statistics from Altmetric.com